Art

J-GLOBAL ID：202302282333991576   Reference number：23A0578688

Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases

神経精神疾患におけるグルタミン酸作動性機能障害の広範な役割の新たなエビデンス【JST・京大機械翻訳】

Author (4)： McGrath Thomas (Green Templeton College, University of Oxford, Oxford OX2 6HG, UK) ,  Baskerville Richard (Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK) ,  Rogero Marcelo (School of Public Health, University of Sao Paulo, Sao Paulo 01246-904, Brazil) ,  Castell Linda (Green Templeton College, University of Oxford, Oxford OX2 6HG, UK)
Material： Nutrients (Web)
Volume： 14  Issue： 5  Page： 917  Publication year： 2022 
JST Material Number： U7255A  ISSN： 2072-6643  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： The monoamine model of depress...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=23A0578688&from=J-GLOBAL&jstjournalNo=U7255A") }}

Thesaurus term： inflammation ,  synapse ,  neural transmission ,  neurotransmitter ,  stress(physiology) ,  clinical trial ,  homeostasis ,  depression(disease) ,  microflora ,  *dysfunction ,  astrocyte ,  dementia ,  Neuronal Plasticity ,  amino acid ,  aliphatic amine ,  aliphatic carboxylic acid ,  carboxamide ,  dicarboxylic acid ,  primary amine

Author keywords (7)： glutamate ,  glutamine ,  excitotoxicity ,  inflammation ,  depression ,  neurodegeneration ,  neuropsychiatric conditions

JST classification (3)： Basic neurology  (GN01020W) ,  Basic psychiatry  (GR01020I) ,  Basic research of psychotropic drugs  (GW03100Y)

Substance index (2)： Glutamine ,  Glutamic acid

Reference (219)：

• James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789-1858.
• Monteggia, L.M.; Malenka, R.C.; Deisseroth, K. Depression: The best way forward. Nature 2014, 515, 200-201.
• Borbély, É.; Simon, M.; Fuchs, E.; Wiborg, O.; Czéh, B.; Helyes, Z. Novel drug developmental strategies for treatment-resistant depression. J. Cereb. Blood Flow Metab. 2021, 179, 1146-1186.
• Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47, 351-354.
• Blaylock, R.L.; Faria, M. New concepts in the development of schizophrenia, autism spectrum disorders, and degenerative brain diseases based on chronic inflammation: A working hypothesis from continued advances in neuroscience research. Surg. Neurol. Int. 2021, 12, 556.

Terms in the title (5)： 神経精神疾患 ,  グルタミン酸 ,  性機能障害 ,  役割 ,  エビデンス